Rockwell Medical Partners with HydroCare to Distribute and Install its Dry Acid Concentrate Mix System
Rockwell Medical (RMTI) has announced a partnership with HydroCare, a provider of dialysis water treatment systems, to distribute and install Rockwell's dry acid concentrate mix system in dialysis water rooms. The partnership involves HydroCare purchasing and installing Rockwell's DAMX45 system, which is 510(k) approved for exclusive use with the company's CitraPure® and Dri-Sate® dry acid concentrate powders.
The DAMX45 system features a forced RO water pump that can mix 100 gallons of acid concentrate on-site in three minutes. This collaboration is expected to generate new sales for Rockwell's dry acid hemodialysis concentrates through expanded mixer installations.
Rockwell Medical (RMTI) ha annunciato una partnership con HydroCare, un fornitore di sistemi di trattamento dell'acqua per dialisi, per distribuire e installare il sistema di miscelazione di acido secco di Rockwell nelle stanze dedicate all'acqua per dialisi. La partnership prevede che HydroCare acquisti e installi il sistema DAMX45 di Rockwell, che è approvato 510(k) per l'uso esclusivo con le polveri di acido secco CitraPure® e Dri-Sate® della società.
Il sistema DAMX45 presenta una pompa per acqua RO forzata che può miscelare 100 galloni di acido concentrato in loco in tre minuti. Questa collaborazione si prevede generi nuove vendite per i concentrati di acido secco per emodialisi di Rockwell grazie all'espansione delle installazioni di miscelatori.
Rockwell Medical (RMTI) ha anunciado una asociación con HydroCare, un proveedor de sistemas de tratamiento de agua para diálisis, para distribuir e instalar el sistema de mezcla de concentrado de ácido seco de Rockwell en las salas de agua para diálisis. La asociación implica que HydroCare compre e instale el sistema DAMX45 de Rockwell, que está aprobado por la FDA 510(k) para uso exclusivo con los polvos de concentrado de ácido seco CitraPure® y Dri-Sate® de la compañía.
El sistema DAMX45 cuenta con una bomba de agua RO forzada que puede mezclar 100 galones de concentrado ácido en el lugar en tres minutos. Se espera que esta colaboración genere nuevas ventas para los concentrados de hemodiálisis de ácido seco de Rockwell a través de la expansión de las instalaciones de mezcladores.
Rockwell Medical (RMTI)는 투석수 처리 시스템 제공업체인 HydroCare와 파트너십을 체결하여 Rockwell의 건식 산 농축 혼합 시스템을 투석수실에 배포 및 설치한다고 발표했습니다. 이 파트너십은 HydroCare가 Rockwell의 DAMX45 시스템을 구매하여 설치하는 것을 포함하며, 이 시스템은 회사의 CitraPure® 및 Dri-Sate® 건식 산 농축 분말과 독점적으로 사용하기 위해 510(k) 승인을 받았습니다.
DAMX45 시스템은 현장에서 3분 만에 100갤런의 산 농축액을 혼합할 수 있는 강제 RO 수압 펌프를 특징으로 합니다. 이번 협업은 믹서 설치 확장을 통해 Rockwell의 건식 산 헤모다이얼리시스 농축액의 새로운 판매를 창출할 것으로 기대됩니다.
Rockwell Medical (RMTI) a annoncé un partenariat avec HydroCare, un fournisseur de systèmes de traitement de l'eau pour dialyse, afin de distribuer et d'installer le système de mélange de concentré d'acide sec de Rockwell dans les salles d'eau de dialyse. Ce partenariat implique qu'HydroCare achète et installe le système DAMX45 de Rockwell, qui est approuvé 510(k) pour une utilisation exclusive avec les poudres de concentré d'acide sec CitraPure® et Dri-Sate® de l'entreprise.
Le système DAMX45 est équipé d'une pompe à eau RO forcée capable de mélanger 100 gallons de concentré d'acide sur site en trois minutes. Cette collaboration devrait générer de nouvelles ventes pour les concentrés d'acide sec en hémodialyse de Rockwell grâce à l'expansion des installations de mélangeurs.
Rockwell Medical (RMTI) hat eine Partnerschaft mit HydroCare, einem Anbieter von Wasseraufbereitungssystemen für die Dialyse, angekündigt, um Rockwells Trockenäurekonzentrat-Mischsystem in Dialyse-Wasser-Räumen zu vertreiben und zu installieren. Die Partnerschaft umfasst den Kauf und die Installation des DAMX45-Systems von Rockwell durch HydroCare, das für die ausschließliche Verwendung mit den Trockenäurekonzentrat-Pulvern CitraPure® und Dri-Sate® des Unternehmens 510(k) genehmigt ist.
Das DAMX45-System verfügt über eine erzwungene RO-Wasserpumpe, die vor Ort in drei Minuten 100 Gallonen Säurekonzentrat mischen kann. Diese Zusammenarbeit wird voraussichtlich neue Verkäufe für Rockwells Trockenäure-Hämodialyse-Konzentrate durch erweiterte Mixer-Installationen generieren.
- New partnership expected to increase sales of dry acid hemodialysis concentrates
- Expansion of distribution network through HydroCare's global presence
- Product efficiency: system can mix 100 gallons in 3 minutes
- None.
Insights
This partnership with HydroCare represents a strategic move to expand Rockwell Medical's market penetration in the hemodialysis sector. The DAMX45 dry acid concentrate mix system, being 510(k) approved and exclusively compatible with Rockwell's proprietary concentrates, creates a valuable recurring revenue stream through both equipment installation and ongoing concentrate sales.
The system's efficiency in producing 100 gallons of acid concentrate in just three minutes addresses key operational pain points in dialysis clinics. The exclusive compatibility with CitraPure® and Dri-Sate® products ensures long-term customer retention and recurring revenue. This type of business model, combining equipment sales with consumables, typically generates higher margins and more predictable revenue streams.
HydroCare's established presence in dialysis water treatment systems provides Rockwell with access to an existing customer base and potentially accelerates market penetration. The partnership could significantly boost Rockwell's installation base and subsequent concentrate sales, though specific financial projections aren't provided in the announcement.
"The dialysis water room is the heartbeat of the dialysis unit, housing the systems that provide highly purified water. It requires regular upkeep to stay clean and toxin-free," says Eric Cirignano, Founder and CEO of HydroCare. "At HydroCare, we focus on providing reliable dialysis water treatment systems that put patient safety first. Our product range includes large RO systems, disposables, and replacement parts. We needed a simple, easy-to-train solution for dry acid mixers, and found that and more with Rockwell Medical’s ‘ready-to-use’ DAMX45 dry acid concentrate mix system."
"We are excited to partner with HydroCare to sell and install our dry acid mixers as part of their dialysis water room installations," said Tim Chole, Chief Commercial Officer at Rockwell Medical. "Our mixer is compact, quick and easy to install, and FDA-approved for Rockwell's dry acid products. Using a forced RO water pump to mix the product, our mixer enables a dialysis clinic to mix 100 gallons of acid concentrate on-site in just three minutes. We believe that this partnership with HydroCare offers us another avenue to install Rockwell's mixers into more clinics to benefit more patients."
About HydroCare
HydroCare isn’t just meeting the dialysis community’s stringent water filtration standards—we're revolutionizing them. Our dialysis water system are engineered to guarantee that patients receive nothing less than the safest, most reliable water for their treatments, every single time. By integrating technologies like reverse osmosis, innovative endotoxin-retentive filters, and cutting-edge pretreatment systems, HydroCare obliterates organic and inorganic contaminants. This is how we redefine the future of dialysis water—pure, compliant, and uncompromising in quality. For more information, visit hydrocare.us.
About Rockwell Medical
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed at freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or in a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work® in 2023 and 2024 and named Fortune Best Workplaces in Manufacturing & ProductionTM in 2024, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis SolutionsTM. For more information, visit www.rockwellmed.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are on track,” “are resolute in our vision,” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. These statements include statements relating to generating new sales and installing the Rockwell Medical mixer into additional dialysis clinics. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2023, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205404760/en/
Heather R. Hunter
SVP, Chief Corporate Affairs Officer
(248) 432-1362
IR@RockwellMed.com
Source: Rockwell Medical
FAQ
What is Rockwell Medical's (RMTI) new partnership with HydroCare about?
How quickly can RMTI's DAMX45 system mix acid concentrate?
What regulatory approval does RMTI's DAMX45 system have?
